Health
Late-Breaking Data at ACC.21 Show XARELTO® (rivaroxaban) Plus Aspirin Significantly Reduced Total Ischemic Events in Peripheral Artery Disease (PAD) Patients After Lower-Extremity Revascularization – PRNewswire
/PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson today presented new data from the Phase 3 VOYAGER PAD study which showed XARELTO®…
RARITAN, N.J., May 16, 2021 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson today presented new data from the Phase 3 VOYAGER PAD study which showed XARELTO® (rivaroxaban) (2.5 mg twice daily) in combination with aspirin (100 mg once daily) consistently reduced severe vascular events in patients with peripheral artery disease (PAD) after lower-extremity revascularization (LER) compared to aspirin alone regardless of whether it was the first, second, third, or subsequent…
-
General23 hours agoGymnastics club in Berwick shuts down following child safety complaint
-
General16 hours agoAshes engulfed by fresh DRS controversy as TV umpire gives Jamie Smith out despite RTS ‘murmur’
-
Noosa News21 hours agoMeticulously crafted home in heart of Noosa Heads
-
General19 hours ago‘Mother’s Day’ solar storm squeezed Earth’s plasmasphere to one-fifth its size